Hanall Biopharma Co

Hanall Biopharma Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Hanall Biopharma Co (009420.KS) as of Nov 2, 2026 is 296.02 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 759.52 % — a change of -61.03% (lower).

FCF Conversion

296.02 %

YoY

-61.03%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Hanall Biopharma Co is 2025 296.02 % . FCF Conversion Rate (FCF/EBITDA) of Hanall Biopharma Co was 2024 759.52 % . It decreases by -61.03% lower compared to the previous year.

The Hanall Biopharma Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-148.88 KRW
Jan 1, 2019
95.80 KRW
Jan 1, 2020
-8.26 KRW
Jan 1, 2021
-42.33 KRW
Jan 1, 2022
8,897.21 KRW
Jan 1, 2023
582.72 KRW
Jan 1, 2024
759.52 KRW
Jan 1, 2025
296.02 KRW
The Hanall Biopharma Co FCF Conversion history
YEARFCF ConversionYoY
296.02 %-61.03%
759.52 %+30.34%
582.72 %-93.45%
8,897.21 %-21,117.05%
-42.33 %+412.36%
-8.26 %-108.63%
95.80 %-164.34%
-148.88 %-121.42%
695.16 %-17,446.39%
-4.01 %-111.64%
34.44 %-8.96%
37.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hanall Biopharma Co Stock analysis

What does Hanall Biopharma Co do? The company Hanall Biopharma Co Ltd was founded in South Korea in 2000 and has since become a leading biopharmaceutical company. The business model of Hanall Biopharma is to develop and market innovative medical products that have the potential to help patients around the world. Hanall Biopharma has several divisions, including the development of biosimilars, where the company has extensive experience. Biosimilars are biological drugs that have a similar effect to an already approved biological drug but can be offered at a lower price. Hanall Biopharma is currently developing several biosimilars, including drugs for the treatment of breast cancer and rheumatoid arthritis. Another important area for Hanall Biopharma is the research and development of novel cancer drugs. The company works closely with renowned research institutes and clinics to identify and develop innovative treatment approaches. The goal is to create drugs that are both more effective and better tolerated than conventional cancer drugs. In addition to these areas, Hanall Biopharma also conducts research and development in many other fields, including neurodegenerative diseases such as Alzheimer's and Parkinson's, rare diseases, and infectious diseases. Hanall Biopharma has also established itself as a provider of research services. Here, the company offers its customers a wide range of services, ranging from drug discovery and development to clinical development. One of Hanall Biopharma's most well-known products is the cancer drug Monoclate-P. This medication is used to treat hemophilia, a rare blood disorder caused by reduced or absent blood clotting. Monoclate-P is the first recombinant factor VIII product manufactured in South Korea. Another significant product of Hanall Biopharma is the cancer drug Abraxane. Abraxane is a nanoparticle-based cancer drug used to treat breast cancer, lung cancer, and pancreatic cancer. Hanall Biopharma has acquired the licensing rights to Abraxane in South Korea and other Asian countries and successfully distributes the medication in these regions. Overall, it remains to be seen how the company Hanall Biopharma Co Ltd will develop in the future. However, given its clear focus on developing innovative medical products and its strong expertise in biotechnology, the future of the company looks promising. Hanall Biopharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hanall Biopharma Co stock

FCF Conversion Rate (FCF/EBITDA) of Hanall Biopharma Co is 296.02 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Hanall Biopharma Co changed from 759.52 % to 296.02 %, representing a -61.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Hanall Biopharma Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Hanall Biopharma Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Hanall Biopharma Co

All Key Metrics — Hanall Biopharma Co